secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kyverna Therapeutics, Inc. (KYTX)
CIK:        0001994702
Form:       8-K
Filed at:   2025-09-25T23:59:59+00:00
Accession:  0001193125-25-217434
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Director Steve Liapis resigns from Kyverna board effective Sept 30, 2025
------------------------------------------------------------------------

- Steve Liapis, Ph.D. notified the board of his resignation effective September 30, 2025.
- Resignation is not due to any disagreement with the company's operations, policies, or practices.
- Board size will be reduced from eight to seven directors upon resignation.
- Christi Shaw, a current board member, appointed to the Audit Committee to fill the vacancy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1994702/000119312525217434/0001193125-25-217434-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1994702/000119312525217434/kytx-20250919.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-217434

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer